JFS Wealth Advisors LLC increased its stake in shares of Novartis AG (NYSE:NVS) by 28.2% during the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 1,752 shares of the company’s stock after buying an additional 385 shares during the quarter. JFS Wealth Advisors LLC’s holdings in Novartis were worth $150,000 at the end of the most recent reporting period.
Other institutional investors also recently made changes to their positions in the company. Fisher Asset Management LLC raised its position in Novartis by 3.4% in the first quarter. Fisher Asset Management LLC now owns 9,657,603 shares of the company’s stock valued at $825,532,000 after purchasing an additional 319,803 shares during the period. Morgan Stanley grew its stake in shares of Novartis by 10.3% in the fourth quarter. Morgan Stanley now owns 2,808,993 shares of the company’s stock valued at $265,253,000 after buying an additional 263,445 shares in the last quarter. Everett Harris & Co. CA grew its stake in shares of Novartis by 206.3% in the fourth quarter. Everett Harris & Co. CA now owns 252,830 shares of the company’s stock valued at $23,875,000 after buying an additional 170,286 shares in the last quarter. OLD Mission Capital LLC grew its stake in shares of Novartis by 85.1% in the third quarter. OLD Mission Capital LLC now owns 367,985 shares of the company’s stock valued at $32,000,000 after buying an additional 169,219 shares in the last quarter. Finally, Brandes Investment Partners LP acquired a new stake in shares of Novartis in the fourth quarter valued at $13,174,000. Hedge funds and other institutional investors own 9.86% of the company’s stock.
NVS has been the subject of a number of research reports. UBS Group reaffirmed a “buy” rating on shares of Novartis in a research note on Monday, April 19th. Barclays reissued an “underweight” rating on shares of Novartis in a research note on Friday, January 22nd. Societe Generale reissued a “buy” rating on shares of Novartis in a research note on Tuesday, March 23rd. Oddo Bhf raised Novartis from a “neutral” rating to an “outperform” rating in a research note on Wednesday, April 28th. Finally, Cowen cut Novartis from an “outperform” rating to a “market perform” rating and lowered their target price for the stock from $110.00 to $105.00 in a research note on Monday, February 1st. Two analysts have rated the stock with a sell rating, three have issued a hold rating and seven have given a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average target price of $108.50.
Novartis (NYSE:NVS) last posted its earnings results on Monday, April 26th. The company reported $1.52 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $1.54 by ($0.02). Novartis had a net margin of 14.71% and a return on equity of 24.39%. The firm had revenue of $12.41 billion during the quarter, compared to analysts’ expectations of $12.63 billion. During the same period in the previous year, the firm posted $1.56 earnings per share. The firm’s revenue for the quarter was up 1.0% on a year-over-year basis. As a group, analysts forecast that Novartis AG will post 5.8 earnings per share for the current year.
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, established, and cardiovascular, renal and metabolism medicine products.
Further Reading: Understanding Price to Earnings Ratio (PE)
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.